Royal Bank Of Canada Rain Therapeutics Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.84 - $1.22 $922 - $1,339	1,098 Added 41.09%	3,770 $4,000
Q3 2023 Nov 14, 2023	BUY	$0.82 - $1.42 $884 - $1,532	1,079 Added 67.73%	2,672 $2,000
Q2 2023 Aug 14, 2023	BUY	$1.09 - $9.93 $1,735 - $15,808	1,592 Added 159200.0%	1,593 $1,000
Q1 2023 May 15, 2023	SELL	$7.77 - $12.47 $7 - $12	-1 Reduced 50.0%	1 $0
Q4 2022 Feb 14, 2023	SELL	$5.52 - $8.48 $121 - $186	-22 Reduced 91.67%	2 $0
Q3 2022 Nov 14, 2022	BUY	$4.75 - $8.01 $114 - $192	24 New	24 $0
Q2 2022 Aug 15, 2022	SELL	$2.21 - $5.56 $2,161 - $5,437	-978 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.07 - $13.68 $13,227 - $35,691	-2,609 Reduced 72.73%	978 $5,000
Q4 2021 Feb 14, 2022	BUY	$11.91 - $17.0 $32,966 - $47,056	2,768 Added 337.97%	3,587 $46,000
Q3 2021 Nov 15, 2021	BUY	$13.21 - $20.91 $2,853 - $4,516	216 Added 35.82%	819 $12,000
Q2 2021 Aug 16, 2021	BUY	$15.08 - $20.3 $9,093 - $12,240	603 New	603 $9,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.